Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 7/20 | 0.34 |
| ▸ | F13A1 | P00488 | 5/20 | 0.34 |
| ▸ | TGM1 | P22735 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778449 | 0.90 | L3MBTL1 (0.43) | MEN1KMT2ANAMPTABL1RIN1 | |
| SCHEMBL6258706 | 0.90 | L3MBTL1 (0.43) | MEN1KMT2ANAMPTABL1RIN1 | |
| SCHEMBL10128793 | 0.84 | GPR119 (0.41) | ALDH1A1 | |
| SCHEMBL7744031 | 0.83 | CCR5 (0.41) | ALDH1A1 | |
| SCHEMBL760419 | 0.80 | GPR119 (0.36) | ALDH1A1TGM2 | |
| SCHEMBL8051176 | 0.67 | PSEN1 (0.40) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8251763 | 0.66 | PSEN1 (0.60) | — | |
| SCHEMBL20379360 | 0.63 | ALDH1A1 (0.47) | MEN1KMT2ANAMPTALDH1A1 | |
| SCHEMBL13405090 | 0.62 | PSEN1 (0.38) | MEN1KMT2APTPN1ALDH1A1L3MBTL1 | |
| SCHEMBL8054683 | 0.62 | PSEN1 (0.38) | MEN1KMT2APTPN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064177-B1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS INC (TW) | 2017-04-05 | — | — | EP | disclosed |
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| EP-1877091-B1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | TAIMED BIOLOG INC (TW) | 2015-03-25 | — | — | EP | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8227450-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILIA BIOPHARMA INC. (CA) | 2012-07-24 | — | — | US | disclosed |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2012-03-01 | — | — | US | disclosed |
| US-8008297-B2 | (1-{5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-phosphonooxy-hexacarbomoyl}-2,2-diphenyl-ethyl)-carbamic acid methyl ester; which upon cleavage of cleavable bond or unit generates HIV-1 aspartyl protease inhibitor; antiviral agent; good solubility, and bioavailability; HIV or HTLV infection | AMBRILIA BIOPHARMA INC. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20100130765-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | AMBRILIA BIOPHARMA INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| EP-2165709-A2 | Lysine based compounds | Ambrilia Biopharma Inc. (CA) | 2010-03-24 | — | — | EP | disclosed |
| EP-2109461-A2 | METHOD FOR IMPROVING PHARMACOKINETICS | Ambrilia Biopharma Inc. (CA) | 2009-10-21 | — | — | EP | disclosed |
| US-20090253926-A1 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILLA BIOPHARMA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| EP-1773763-B1 | LYSINE BASED COMPOUNDS | AMBRILIA BIOPHARMA INC (CA) | 2008-12-17 | — | — | EP | disclosed |
| US-20080269172-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2008-10-30 | — | — | US | disclosed |
| US-7388008-B2 | Lysine based compounds | AMBRILIA BIOPHARMA INC. (CA) | 2008-06-17 | — | — | US | disclosed |
| WO-2008023273-A2 | METHOD FOR IMPROVING PHARMACOKINETICS | AMBRILIA BIOPHARMA INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1877091-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | Ambrilia Biopharma Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | MEN1 2117/4885KMT2A 12/4885NAMPT 2013/4885 |
| US-20090253926-A1 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | PREP, SPINT2, DNPEP | MEN1 1910/4885KMT2A 205/4885NAMPT 668/4885 |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | MEN1 3286/4885KMT2A 1225/4885NAMPT 1365/4885 |
| US-20080269172-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | MEN1 2117/4885KMT2A 12/4885NAMPT 2013/4885 |
| US-20100130765-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | PREP, SPINT2, HPN | MEN1 1915/4885KMT2A 198/4885NAMPT 697/4885 |
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | MEN1 4812/4885KMT2A 1619/4885NAMPT 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.